Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence.

IF 2.8 3区医学 Q2 ONCOLOGY Expert Review of Anticancer Therapy Pub Date : 2025-02-06 DOI:10.1080/14737140.2025.2463486

Pian Wang, Xinmiao Zhang, Jinhai Shen

{"title":"Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence.","authors":"Pian Wang, Xinmiao Zhang, Jinhai Shen","doi":"10.1080/14737140.2025.2463486","DOIUrl":null,"url":null,"abstract":"Background: The prognostic impact of renin-angiotensin system inhibitors (RASIs) on ovarian cancer (OC) remains indeterminate. This meta-analysis aims to consolidate real-world data to provide a comprehensive, evidence-based assessment of the association between RASIs use and clinical outcomes in OC patients.Methods: A meticulous search strategy was devised and executed across PubMed, Scopus, and Embase databases to retrieve all relevant studies evaluating the prognostic impact of RASIs in patients with OC. Studies comparing survival outcomes between RASIs users and non-users were included in the meta-analysis.Results: A total of six studies, encompassing 11 cohorts and 14,634 patients, were included in the meta-analysis. RASIs use was found to be significantly correlated with enhanced survival (HR: 0.82; 95%CI: 0.72-0.92) in the OC patient population. Subgroup analysis showed that ACEIs use (HR: 0.83, 95% CI: 0.78-0.89) and post-diagnostic RASIs use (HR: 0.77, 95% CI: 0.66-0.90) significantly improved overall survival.Conclusion: This meta-analysis provides evidence that RASIs are associated with improved prognosis in OC patients. These findings suggest that RASIs may have potential as an adjunctive therapy in the management of OC, warranting further investigation and consideration in clinical management protocols.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.8000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2463486","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The prognostic impact of renin-angiotensin system inhibitors (RASIs) on ovarian cancer (OC) remains indeterminate. This meta-analysis aims to consolidate real-world data to provide a comprehensive, evidence-based assessment of the association between RASIs use and clinical outcomes in OC patients.

Methods: A meticulous search strategy was devised and executed across PubMed, Scopus, and Embase databases to retrieve all relevant studies evaluating the prognostic impact of RASIs in patients with OC. Studies comparing survival outcomes between RASIs users and non-users were included in the meta-analysis.

Results: A total of six studies, encompassing 11 cohorts and 14,634 patients, were included in the meta-analysis. RASIs use was found to be significantly correlated with enhanced survival (HR: 0.82; 95%CI: 0.72-0.92) in the OC patient population. Subgroup analysis showed that ACEIs use (HR: 0.83, 95% CI: 0.78-0.89) and post-diagnostic RASIs use (HR: 0.77, 95% CI: 0.66-0.90) significantly improved overall survival.

Conclusion: This meta-analysis provides evidence that RASIs are associated with improved prognosis in OC patients. These findings suggest that RASIs may have potential as an adjunctive therapy in the management of OC, warranting further investigation and consideration in clinical management protocols.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肾素-血管紧张素系统抑制剂对卵巢癌患者预后的影响：真实世界证据的荟萃分析。

背景：肾素-血管紧张素系统抑制剂（RASIs）对卵巢癌（OC）的预后影响仍不确定。本荟萃分析旨在整合真实世界的数据，以提供一个全面的、基于证据的评估RASIs使用与OC患者临床结果之间的关系。方法：在PubMed、Scopus和Embase数据库中设计并执行了一项细致的搜索策略，以检索评估RASIs对OC患者预后影响的所有相关研究。meta分析包括比较RASIs使用者和非使用者之间生存结果的研究。采用漏斗图和Egger检验评估发表偏倚风险。采用留一方法进行敏感性分析，以确保合并估计的稳健性和可靠性。结果：荟萃分析共纳入6项研究，包括11个队列和14,634名患者。RASIs的使用与生存率的提高显著相关(HR: 0.82；95%CI: 0.72-0.92)。亚组分析显示，使用acei （HR: 0.83, 95% CI: 0.78-0.89）和诊断后使用RASIs （HR: 0.77, 95% CI: 0.66-0.90）显著提高了总生存率。敏感性分析证实了合并结果的一致性和稳定性。结论：该荟萃分析提供了RASIs与OC患者预后改善相关的证据。这些发现表明，RASIs可能有潜力作为一种辅助治疗，在OC的管理，值得进一步研究和考虑临床管理方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.